Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ACTU Actuate Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: ACTU
Price (delayed)
$9.65
Market cap
$188.48M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.26
Enterprise value
$179.84M
We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We
Highlights
The EPS has surged by 81% year-on-year and by 79% since the previous quarter
Actuate Therapeutics's quick ratio has soared by 128% YoY but it has decreased by 38% from the previous quarter
Actuate Therapeutics's equity has soared by 100% YoY but it has plunged by 98% from the previous quarter
Key stats
What are the main financial stats of ACTU
Market
Valuations
Earnings
Shares outstanding
19.53M
Market cap
$188.48M
Enterprise value
$179.84M
Price to earnings (P/E)
N/A
Price to book (P/B)
1,809.07
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$25.16M
Net income
-$27.29M
EBIT
-$27.27M
EBITDA
-$27.27M
Free cash flow
-$21.84M
Per share
Balance sheet
Liquidity
EPS
-$3.26
EPS diluted
-$3.26
Free cash flow per share
-$2.61
Book value per share
$0.01
Revenue per share
$0
TBVPS
$1.11
Total assets
$9.32M
Total liabilities
$9.21M
Debt
$0
Equity
$104,186
Working capital
$405,397
Debt to equity
0
Current ratio
1.05
Quick ratio
0.98
Net debt/EBITDA
0.32
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-389.6%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-5,284.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACTU stock price
How has the Actuate Therapeutics stock price performed over time
Intraday
0.1%
1 week
3.76%
1 month
20.63%
1 year
N/A
YTD
21.23%
QTD
42.54%
Financial performance
How have Actuate Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$25.16M
Net income
-$27.29M
Gross margin
N/A
Net margin
N/A
ACTU's net income is down by 10% YoY but it is up by 4.1% from the previous quarter
Actuate Therapeutics's operating income has increased by 4% from the previous quarter
Price vs fundamentals
How does ACTU's price correlate with its fundamentals
Growth
What is Actuate Therapeutics's growth rate over time
Valuation
What is Actuate Therapeutics stock price valuation
P/E
N/A
P/B
1,809.07
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 81% year-on-year and by 79% since the previous quarter
Actuate Therapeutics's equity has soared by 100% YoY but it has plunged by 98% from the previous quarter
Efficiency
How efficient is Actuate Therapeutics business performance
Actuate Therapeutics's ROA has plunged by 85% YoY but it has increased by 26% from the previous quarter
Dividends
What is ACTU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACTU.
Financial health
How did Actuate Therapeutics financials performed over time
The current ratio has soared by 144% YoY but it has contracted by 38% from the previous quarter
Actuate Therapeutics's quick ratio has soared by 128% YoY but it has decreased by 38% from the previous quarter
ACTU's debt is 100% lower than its equity
Actuate Therapeutics's equity has soared by 100% YoY but it has plunged by 98% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.